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Sprifermin (rhFGF18) versus vehicle 
induces a biphasic process of 
extracellular matrix remodeling in 
human knee OA articular cartilage 
ex vivo
D. Reker1,2, A. S. Siebuhr  1, C. S. thudium1, T. Gantzel3, C. Ladel4, M. Michaelis4, A. Aspberg  5, 
M. W. Berchtold2, M. A. Karsdal1, A. Gigout4 & A. C. Bay-Jensen  1*
Sprifermin, recombinant human fibroblast growth factor 18 (rhFGF18), induces cartilage regeneration 
in knees of patients with osteoarthritis (OA). We hypothesized that a temporal multiphasic process of 
extracellular matrix (ECM) degradation and formation underlie this effect. We aimed to characterize 
the temporal ECM remodeling of human knee OA articular cartilage in response to sprifermin 
treatment. Articular cartilage explants from patients with knee OA (npatients = 14) were cultured for 
70 days, with permanent exposure to sprifermin (900, 450, 225 ng/mL), FGF18 (450 ng/mL), insulin-
like growth factor-1 (100 ng/mL, positive control) or vehicle (nreplicates/treatment/patient = 2). Metabolic 
activity (AlamarBlue) and biomarkers of type IIB collagen (PIIBNP) formation (Pro-C2 enzyme-linked 
immunosorbent assay [ELISA]) and aggrecanase-mediated aggrecan neo-epitope NITEGE (AGNx1 
ELISA) were quantified once a week. At end of culture (day 70), gene expression (quantitative reverse 
transcription polymerase chain reaction) and proteoglycan content (Safranin O/Fast green staining) 
were quantified. The cartilage had continuously increased metabolic activity, when treated with 
sprifermin/FGF18 compared to vehicle. During days 7–28 PIIBNP was decreased and NITEGE was 
increased, and during days 35–70 PIIBNP was increased. At end of culture, the cartilage had sustained 
proteoglycan content and relative expression of ACAN < COL2A1 < SOX9 < COL1A1, indicating that 
functional chondrocytes remained in the explants. Sprifermin induces a temporal biphasic cartilage 
remodeling in human knee OA articular cartilage explants, with early-phase increased aggrecanase 
activity and late-phase increased type II collagen formation.
Disease-modifying osteoarthritis drugs (DMOADs) that halt or prevent the progressive degeneration of joint 
tissues in osteoarthritis (OA), are urgently needed. Such drugs may either inhibit one or more of the catabolic 
processes of OA (anti-catabolic approach), induce regenerative processes in OA tissues (anabolic approach), or 
a combination of both. Several anabolic DMOADs have been investigated and shown anabolic effects on carti-
lage1, but it has proven challenging to provide convincing evidence of their clinically relevant effects on patients 
(reviewed by Hunter et al. 20112).
Sprifermin is the first DMOAD candidate shown to induce cartilage regeneration in the knees of patients 
with OA. This was demonstrated in the 2-year primary endpoint data from the currently ongoing 5-year phase II 
clinical trial of sprifermin in knee OA3. Treatments with sprifermin consisting of one injection/week for 3 weeks 
resulted in a dose-dependent increase in total femorotibial joint cartilage thickness. Previous clinical trials and 
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animal studies have also shown regenerative effects of sprifermin on joint cartilage4–8. Meanwhile, no local, sys-
temic or serious safety concerns have been reported with intra-articular administration of sprifermin3–5.
The cartilage regenerative effect of sprifermin is driven by activation of the fibroblast growth factor receptor 
3 (FGFR3) on the surface of chondrocytes9,10. Sprifermin is roughly five times more potent on this receptor com-
pared to the natural ligand human fibroblast growth factor 18 (FGF18). The activation of FGFR3 induces pro-
liferation, while maintaining the chondrogenic phenotype10–13. In addition, it induces formation of extracellular 
matrix (ECM) molecules type II collagen and aggrecan8–12,14.
We have previously shown a temporal ECM remodeling effect of sprifermin on bovine articular cartilage 
explants12. This study demonstrated that indeed chondrocytes could be reached and activated by sprifermin 
through the ECM of the explant and identified two response biomarkers: PRO-C2, reflecting type II collagen 
formation (the propeptide PIIBNP), and AGNx1, reflecting aggrecanase-mediated aggrecan degradation (the 
NITEGE fragment). Interestingly, NITEGE was released earlier than PIIBNP, indicating that early ECM deg-
radation may be part of the regeneration process ultimately leading to increased ECM formation. Moreover, 
chondrocyte cultures (both monolayer and 3-dimensional) revealed an inverse linear correlation between pro-
liferation and ECM formation, suggesting that chondrocytes cannot efficiently proliferate and produce ECM 
simultaneously11.
In summary, investigations on the FGF18 mode of action in chondrocyte monolayers and 3D cultures, as well 
as bovine explant show that FGF18 induce cell-proliferation and cartilage formation independently. Based on 
these observations, we investigated the effect of sprifermin on human OA cartilage and its ability to induce car-
tilage remodeling through a temporal multiphasic process of ECM degradation and ECM formation. ECM deg-
radation and formation were monitored over time by measuring the release of NITEGE (aggrecanase-mediated 
aggrecan degradation) and PIIBNP (type IIB collagen formation), respectively. These biomarkers of ECM remod-
eling were identified in the previous bovine articular cartilage explants studies12. Ultimately, cartilage quality 
resulting from ten weeks of ex vivo culture was assessed by Safranin O/Fast green stainings (proteoglycan content) 
and gene expression analyses (COL2A1, ACAN, SOX9 and COL1A1 expression). Cartilage specimens from 14 
patients were analyzed, to account for heterogeneity of the patient population.
Methods
Human knee OAarticular cartilage explants culture. To investigate the cellular and extracellular com-
ponents of human knee OA articular cartilage in response to sprifermin, the well-described cartilage explant 
model was used15–22.The explants were cultured in serum-free medium to avoid interference from growth factors 
and proteolytical enzymes.
Reagents. Human knee OA articular cartilage was obtained from the Department of Orthopedics at Gentofte 
University Hospital, Denmark, following international ethical guidelines for handling human samples and patient 
information (approved by the Danish National Committee on Biomedical Research Ethics, Department of Health, 
approval no. H D-2007-0084). All participants signed informed consent prior to enrolment in the study. The cul-
ture medium was composed of DMEM/Nutrient Mixture F-12 with GlutaMAX (DMEM/F12-GlutaMAX) with 
1% Penicillin Streptomycin (PS) both obtained from Life Technologies. Phosphate buffered saline and human 
insulin-like growth factor-1 (IGF-1) were obtained from Sigma-Aldrich. FGF18 was obtained from Abcam. The 
sprifermin used was drug product formulated for intra-articular administration obtained from Merck KGaA 
together with the corresponding vehicle formulation. The vehicle formulation contained 7 mM Na2HPO4, 1 mM 
KH2PO4, 2.7 mM KCl (pH 7.3). Selection of doses was based on in vivo pharmacodynamic data published by 
Gigout et al. in 2017, where does between 100 and 1000 ng/mL were most effective11. The doses were confirmed 
and narrowed to 300 to 900 ng/mL by studies in bovine cartilage explant published by Reker et al. in 201712.
Tissue preparation. Human knee OA articular cartilage was harvested from macroscopically undamaged 
areas from femoral condyles of knee joint of OA patients undergoing knee replacement surgery due to knee OA. 
The cartilage was dissected from the bone by scraping a scalpel to the surface of the bone ensuring that all layers of 
the cartilage was included. Cartilage from the rim of the condyles were excluded. The scrap-offs were immediately 
transferred to sterile tubes containing culture medium and stored at 4 °C for maximum 2days.Age and gender of 
the patients is known to the surgeon however blinded to researchers, as depicted in the ethical permit issued by 
The Danish Science Ethical committee, Region of Copenhagen (H-D-2007-0084). Patient consent to have their 
remnant cartilage used for research without personal information attached.Cartilage plugs (i.e., explants) were 
isolated using a 3 mm diameter biopsy punch (Miltex), and the isolated explants (10–20 mg, 2–3 mm in height) 
were randomly distributed in 96-well culture plates with two explants per well. The explants were washed three 
times in culture medium and cultured in DMEM/F12-GlutaMAX with 1% PS at 37 °C, 5% CO2.
Study design. Articular cartilage viable (based on metabolic activity) explants from 14 OA patients were 
included in the study.Explants from each patient were exposed to all treatments. From each patient, two plugs 
were added to each well, and two wells were used for each treatment arm (a total of 12 plugs per patients). 
However, due to limitations in tissue volume, a few exceptions had only one replicate well (see Supplementary 
Table 1, Additional File 3).The explants were cultured for 70 days. The 70-day incubation period was decided 
after several feasibility studies (data not shown). Once a week, conditioned medium was collected and stored at 
−20 °C for further analyses. Immediately after, freshly prepared medium with the following additions was add-
ed:Sprifermin (900, 450, 225 ng/mL), FGF18 (450 ng/mL), IGF-1 (100 ng/mL, positive control) orvehicle formu-
lation (negative control). Hence, treatments were permanentlypresent in the medium. At termination (day 70), 
the explants were either fixed in 4% formaldehyde (npatients = 8)or snap-frozen in liquid nitrogen (npatients = 6) for 
further analyses.
3Scientific RepoRtS |         (2020) 10:6011  | https://doi.org/10.1038/s41598-020-63216-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
Metabolic activity. AlamarBlue reagent (Life Technologies) was used as a non-toxic reagent for quantifying 
the metabolic activity of the explants at baseline (day 0) and once a week during culturing in the conditioned 
medium. The assay was performed as previously described12.Only explants with measurable activity (n = 14) at 
baseline was continued to further experiments (Fig. S-6).
Biochemical markers of ECM remodeling. PRO-C2enzyme-linked immunosorbent assay (ELISA). The 
PRO-C2 ELISA (Nordic Bioscience) was used to quantify levels of type IIB collagen (PIIBNP) formation17. The 
PRO-C2 is a competitive ELISA that detects the PIIBNP propeptide (QDVRQPG), which is released during 
trimming of newly synthesized type II collagen by N propeptidases in the ECM. The assay was performed as 
previously described12.
AGNx1 ELISA. The AGNx1 ELISA (Nordic Bioscience) was used to quantify aggrecanase-mediated aggrecan 
degradation22. The AGNx1 is a competitive ELISA that detects the C-terminal peptide (NITEGE373) generated 
by aggrecanase cleavage. This ELISA recognizes all cleavage fragments that contain an exposed NITEGE epitope, 
thus including the 32 mer fragment (described by Lees et al.23), fragments with the G1 domain and even larger 
fragments with hyaluronic acid still linked to the G1 domain. The assay was performed as previously described12.
Gene expression analyses. RNA extraction. The RNAqueous Kit (Ambion, AM1912) was used to 
extract total RNA from N2-preserved cartilage explants. Due to the low expected quantity of RNA in the cartilage 
explants, the four explants from each patient/treatment group were pooled. The RNAqueous Kit protocol guide-
lines for RNA extraction from “Frozen, hard-consistency, or RNase-rich tissue samples” were followed. Briefly, 
the frozen cartilage was pulverized in a pre-chilled bead mill, immediately transferred to the kit lysis/binding 
solution, and frozen at −80 °C. Prior to RNA extraction, samples were incubated at room temperature (RT) 
for 30 min and then centrifuged to remove debris. The standard kit protocol was followed for RNA extraction 
through glass fiber filters, and RNA yield and quality were assessed by NanoDrop spectrophotometry.
cDNA synthesis. First strand cDNA was synthesized using the Maxima First Strand cDNA Synthesis Kit for 
quantitative reverse transcription polymerase chain reaction (RT-qPCR) (Thermo Scientific, #K1641), following 
the supplied protocol. Due to low RNA yield from the cartilage explants, the maximum amount of RNA was 
added to the reaction.
RT-qPCR. TaqMan Gene Expression Assays were used together with TaqMan Fast Advanced Master Mix to 
quantify expression of the reference gene human EIF3I (assay ID Hs01116184_g1) and the target genes human 
COL2A1 (assay ID Hs00264051_m1), human ACAN (assay ID Hs00153936_m1),human SOX9 (assay ID 
Hs00165814_m1), and human COL1A1 (assay ID Hs00164004_m1).The supplied protocol was followed, again 
maximizing the amount of template cDNA, due to the low yield from cartilage explants. A non-template control 
was included for each assay, andan inter-plate control reaction quantifying EIF3I in a quality control sample was 
included on each plate. All reactions were run in triplicates. The RT-qPCR reactions were run on a StepOnePlus 
Real-Time PCR Instrument. The relative expression for each target gene in each sample were calculated by the 
2−ΔΔCt method, using EIF3I as reference gene. Levels were normalized to the vehicle group. Non-detectable reac-
tions were excluded from analysis, and samples with non-detectable EIF3I were entirely excluded.
Cartilage tissue staining. Safranin O/Fast Green. The histochemical staining Safranin O/Fast Green 
was used to visualize the proteoglycan content of formalin-fixed paraffin-embedded (FFPE) tissue slides of 
explants from 3 patients. Briefly, explants isolated at termination (day 70) were fixed in 4% formaldehyde (Merck 
Millipore) for 2 hours at RT and embedded in paraffin. Sections of 5 μm were cut across the cartilage layers, 
so that all slides included both the superficial, middle and deep layer of the cartilage. The sections were taken 
through de-paraffination and hematoxylin staining before staining first with Fast Green and then Safranin O. 
Sections were then dehydrated and mounted.
Statistics. First, the dataset for each individual patient was calculated; each individual explant was 
baseline-corrected by dividing the value at each time point by the baseline value (day 0). Then, each individual 
explant was vehicle-corrected by dividing the baseline-corrected value at each time point by the correspond-
ing baseline-corrected mean value of the vehicle-treated explants from the same patient. Second, the individual 
patient datasets were combined, by transferring the mean value for each patient and treatment group. The com-
bined patient dataset was reported as median±95% confidence interval (n = 11).At single time points, medians 
of the treatment groups were compared to the vehicle group with Kruskal-Wallis test, using Dunn’s multiple 
comparisons test to correct for multiplicity. Statistical tests were performed in Graph-Pad Prism 6.0. Significance 
levels are indicated by exact p values.
Results
Model controls. Before further analyses were performed, two parameters were evaluated in all patients. First, 
the metabolic activity, assessed once a week, which in general was sustained at about 50% of the baseline (day 
0) value after ten weeks of culture. Explants that dropped below 30% of their baseline value, were excluded from 
further analyses. Second, we evaluated PIIBNP response to IGF-1, which in most patient was increased to around 
100 ng/mL (average of replicate explants) peaking within the first 3 weeks of culturing (day 7–21). In order to 
detect differences between treatment groups, only patients that had IGF-1 inducible levels of PIIBNP. In total, 3 
patients were entirely excluded based on these two parameters (patient 3, 7 and 12). An overview of the number 
of explants and patients per treatment can be found in the additional files (Table S1).
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Sprifermin continuously increases metabolic activity of human OA cartilage explants. The 
metabolic activity was monitored in cartilage explants from 11 patients after 0, 7, 14, 21, 28, 35, 42, 49, 56, 63 
and 70 days of culture with either sprifermin, FGF18 or vehicle treatment.Mean baseline levels of the metabolic 
activity patients were 10053 (3003) mAbs (Fig. S6).
Metabolic activity was continuously increased by sprifermin and by FGF18 compared to vehicle, when com-
paring the medians of the 11 OA patients (Fig. 1A). By termination of the study (day 70), all investigated doses 
of sprifermin and of FGF18 were significantly increased by 58% or more,compared to vehicle(p ≤ 0.005, Fig. 1B).
When evaluating the individual patients, all patients responded with increased metabolic activity at all time 
points, but the exact pattern of the response (response-rate and time points of maximum effect) varied from 
patient to patient (Fig. S1). There were not significant differences observed between the different doses of spri-
fermin (Fig. 1B).
Sprifermin induces biphasic ECM remodeling of human OA cartilage explants. To evaluate the 
temporal effect of sprifermin on ECM remodeling in human OA cartilage tissue, the biomarkers PRO-C2, AGNx1 
and glycosaminoglycan (GAG; see Supplementary Methods, Additional File 1)were quantified in the conditioned 
media harvested from cartilage explants from 11 patients (GAG only in 5 patients) after 0, 7, 14, 21, 28, 35, 42, 49, 
56, 63 and 70 days of culture with either sprifermin, FGF18 or vehicle treatment.
Type II collagen formation, reflected by PIIBNP, was modulated by sprifermin/FGF18 in a biphasic fash-
ion compared to vehicle;PIIBNPwas decreasedduring early-phase culturing (day 7–28) and increased during 
late-phase culturing (day 35–70), when comparing the medians of the 11 OA patients to the vehicle control 
(Fig. 2A). The maximum early-phase decrease (day 21) was 31% for sprifermin (450 ng/mL, not significant) and 
41% for FGF18 (p = 0.004). The maximum late-phase increase (day 49) was dose-dependent and significant for all 
investigated doses of sprifermin, compared to vehicle (p ≤ 0.015, Fig. 2B). The effect of FGF18 at day 49 (response 
peak) point was 23% increase (not significant), hence, much less pronounced than the comparative concentration 
of sprifermin (450 ng/mL), showing a 66% increase(p = 0.007, Fig. 2B). When evaluating the individual patients, 
all but one patient (patient 9) responded in a biphasic fashion (Fig. S2G). However, 3 patients (patient 9, 10 and 
14) did not show the early-phase decrease (Fig. S2G,H,K), and 2 patients (patient 6 and 8) did not show the 
late-phase increase (Fig. S2E,F).
Aggrecanase-mediated aggrecan degradation, reflected by NITEGE, also revealed a biphasic response to spri-
fermin/FGF18 compared to vehicle. In contrast to PIIBNP, NITEGE was increased during early-phase culturing 
(day 7–28) and unchanged or decreased during late-phase culturing (day 35–70), when medians of the 11 OA 
patients were compared (Fig. 2C). The maximum early-phase increase (day 21) was significant for all investigated 
doses of sprifermin and FGF18, compared to vehicle (p ≤ 0.042).Although FGF18 had a significant effect of 21% 
(p = 0.042), it was clearly lower than the 52% increase by sprifermin 450 ng/mL (p = 0.0005) at day 21 (peak 
response) (Fig. 2D). When evaluating the individual patients, all but 2 patients (patient 2 and 8) responded in a 
biphasic fashion (Fig. S3F). Those 2 patients did not have the late-phase decrease/no change, but rather a con-
tinuous increase throughout culturing. In addition, one patient (patient 9) did not have the early-phase increase 
(Fig. S3G).
Glycosaminoglycan release, reflected by GAG, did not significantly respond to sprifermin compared to vehi-
cleat any time point, when medians of 5 OA patients were compared (Fig. S4A). FGF18 induced a small, but 
significant increase in GAG during early phase (day 21; Fig. S4B).
Figure 1. Metabolic activity (AlamarBlue) over time, patients combined (n = 11).Metabolic activity of human 
OA cartilage explants during ten weeks of culture. Patient 1, 2, 4, 5, 6, 8, 9, 10, 11, 13 and 14 were included. 
Explants were incubated 3 hours with 10% Alamar Blue® (A) The patient means (the mean of two replicate 
explants from each patient, calculated after baseline- and vehicle-correction) were combined and presented 
as median ±95% CI. (B) The medians ±95% CI of day 70 are presented. Significance level to vehicle was 
determined by Kruskal-Wallis test, using Dunn’s multiple comparisons test to correct for multiplicity, and p-
values ≤ 0.05 are indicated above each treatment group.
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Cartilage was sustained throughout ten weeks of ex vivo culture. To evaluate the terminal (day 
70) quality of the human OA cartilage tissue after ten weeks of ex vivo culture, gene expression analyses and his-
tochemical staining were performed oncartilage explants harvested at study termination, after 70 days of culture 
with either sprifermin, FGF18 or vehicle treatment.
The relative expression of chondrocyte phenotype markers COL2A1 (encoding type II collagen), ACAN 
(encoding aggrecan) and SOX9 (encoding the chondrogenic transcription factor Sox9), and fibrocartilage marker 
COL1A1 (encoding type I collagen)was indicative of a hyaline cartilage. ACAN and COL2A1 were expressed at 
detectable levels in all patients, whereas SOX9 and COL1A1 were detected in most patients (Table 1). The relative 
expression of ACAN and COL1A1 was trending towards lower levels in the FGF18 and sprifermin group(Ta-
ble 1). However, no significant difference in relative expression was observed betweensprifermin, FGF18, when 
comparing the medians of the 3–5 OA patients with detectable levels (Table 1).
Cartilage explants from fixated and stained with fast green and safranin O at the day 70, to visually assess the 
proteoglycan content. Figure 3 depicts three representative patients and the superficial (upper), mid and deep 
zone (bordering to the calcified cartilage). Proteoglycan was gradually lost from the superficial zone to the deep 
zone, as observed by green to deep red color. In agreement with the gene expression analyses, no visual differ-
ence between treatment arms in red coloration of cartilage sections from different areas of the cartilage, could be 
observed at the end of the termination of the study (Fig. 3).
Discussion
The data from this study suggests that sprifermin stimulates human articular cartilage from 11 knee OA patients 
undergoing total knee replacementin a temporal biphasic fashion that eventually results in production of hya-
line cartilage. To summarize, the cartilage explants permanently stimulated with sprifermin had continuously 
increased metabolic activity throughout the culture period (day 0–70). Duringearly-phase culturing (day 7–28) 
Figure 2. ECM remodeling (PIIBNP and NITEGE) over time, patient combined (n = 11).TypeII collagen 
formation (A,B) and aggrecanase-mediated aggrecan degradation (C,D) of human OA cartilage explants 
during 10 weeks of culture. Patient 1, 2, 4, 5, 6, 8, 9, 10, 11, 13 and 14 were included. The ECM remodeling was 
measured by PRO-C2 and AGNx1 ELISAs in conditioned media collected weekly during culturing. (A,C) The 
patient means (the mean of two replicate explants from each patient, calculated after baseline- and vehicle-
correction) were combined and presented as median ±95% CI. (B,D) The medians ±95%CI of day 49 and 21 
(peak response), for PIINAP and NITEGE releases respectively, are presented. Significance level to vehicle was 
determined by Kruskal-Wallis test, using Dunn’s multiple comparisons test to correct for multiplicity, and p-
values ≤ 0.05 are indicated above each treatment group.
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the explants had increased aggrecanase-mediated aggrecandegradation (NITEGE) and decreased type II colla-
gen formation (PIIBNP), whereas the late-phase showed increased type II collagen formation.This investigation 
builds on a previous study that investigate the effect on human and porcine monolayer chondrocyte cultures11 and 
bovine cartilage explants12. In current model we use OA human cartilage which is known to be more heteroge-
nous than that of healthy bovine cartilage cultures. With current study, we aimed to support and confirm previous 
finding that there may be biphasic ECM remodeling effect of FGF18 and sprifermin on articular cartilage, using 
material that is translational to real life settings.
In the early phase of culturing, the chondrocytes of sprifermin-treated explants seemed to exhibit a catabolic 
phenotype, with decreased PIIBNP release and increased NITEGE release. The NITEGE release was previously 
seen in bovine articular cartilage, where it was suggested to be part of a coordinated process to expand the lacu-
nae and allow proliferation of chondrocytes12. In the present study, it was not possible to monitor the temporal 
changes in cell proliferation. However, the increasing metabolic activity during the early phase could very well 
reflect a growing chondrocyte population. If the chondrocytes are actively proliferating in the early phase, then 
ECM formation should be compromised, assuming a negative linear correlation between proliferation and ECM 
formation as previously shown11. This would explain the decreased PIIBNP release. In previous published work it 
has been shown that proliferation is indeed induced by sprifermin; alginate cultures of human primary chondro-
cyte show up to a 4-fold increase in cell numbers when stimulated with sprifermin.
In the late phase of culturing, the chondrocytes of sprifermin-treated explants exhibited an anabolic pheno-
type. The aggrecanase activity responsible for the NITEGE release during early-phase culturing was gone, while 
type II collagen formation was increased. If ECM degradation is a prerequisite for chondrocyte proliferation, 
which in turn compromises parallel ECM formation, then the late phase seems to be the time where active pro-
liferation has been completed and chondrocytes produce new ECM, which could also be reflected in the further 
increasing metabolic activity.
The sprifermin-induced ECM remodeling effects observed were superior to the effects of the natural ligand 
FGF18, potentially due to the roughly five times higher potency of sprifermin on the FGFR3 receptor. Meanwhile, 
the effect on metabolic activity of the explants were similar for sprifermin and FGF18 at the dose level tested in 
this study (450 ng/mL). Lower doses would maybe be able to differentiate the two.
To the best of our knowledge, sprifermin has proven to be anabolic in studies from bench to bedside. We 
therefore hypothesize that the catabolic effects suggested by the present study, are part of a coordinated sequen-
tial process leading to cartilage regeneration. Indeed, data obtained at termination of this study (day 70) show 
highly metabolically active chondrocytes (metabolic activity and expression of ECM molecules remains), with 
no indication of chondrocytes with an aberrant phenotype. The genetic markers could not discriminate between 
sprifermin and vehicle, potentially due to the indirect normalization to the number of cells (through the endoge-
nous reference gene), in turn eliminating the effect of proliferation.
The biphasic process of ECM remodeling observed in this study may be indicative of the events occurring in 
the knees of OA patients treated with sprifermin in a clinical setting. Despite the limitations of the ex vivo model 
used in the present study, several translational parameters exist. (1) The articular cartilage specimens used in the 
present study were retrieved from knee OA patients scheduled for knee replacement surgery. Likewise, the OA 
patients enrolled in the latest clinical study have symptomatic radiographic knee OA, Kellgren-Lawrence grade 
2 or 3. (2) The ex vivo model studies the articular cartilage, with chondrocytes residing in their natural matrix. 
(3) In both ex vivo and in vivo studies, sprifermin is added directly to the articular cartilage either by addition 
to the culture media or by intra-articular injections into the synovial cavity. (4) The dose levels used ex vivo are 
physiologically relevant.
If biphasic ECM remodeling occurs in the articular cartilage of sprifermin-treated knee OA patients, the 
NITEGE release might be interesting in several ways. First, one could speculate whether AGNx1 could be used 
as an early efficacy biomarker for sprifermin. In the present study, no clear correlation could be found between 
responders/non-responders of PIIBNP and early-phase NITEGE release. Data are very limited as only 2 patients 
(patient 6 and 8) did not respond by increased late phase PIIBNP. Second, the NITEGE fragment may have 
Vehicle FGF18 450 ng/mL Sprifermin 900 ng/mL Sprifermin 450 ng/mL
Sprifermin 
225 ng/mL
Kruskal-Wallis 
test (p-value)
COL2A1 1n = 5/5
1.93(0.71–2.00)
n = 3/3
0.81 (0.60–1.99)
n = 5/5
0.81 (0.30–2.92)
n = 5/5
1.41(0.39–3.65)
n = 4/4 >0.1
ACAN 1n = 5/5
0.84 (0.25–2.21)
n = 3/3
0.57 (0.97–0.51)
n = 5/5
0.34 (0.17–0.92)
n = 5/5
0.63 (0.27–1.85)
n = 4/4 0.041
SOX9 1n = 5/5
1.01 (1.00–2.22)
n = 3/3
1.22 (0.42–2.38)
n = 5/5
0.65 (0.23–1.01)
n = 4/5
2.04 (0.43–5.55)
n = 4/4 >0.1
COL1A1 1n = 4/5
0.40 (0.10–0.70)
n = 3/3
1.91 (1.76–2.06)
n = 3/5
0.66 (0.41–1.71)
n = 3/5
0.25 (0.11–0.43)
n = 4/4 0.012
Table 1. COL2A1, ACAN, SOX9 and COL1A1 fold expression (RT-qPCR) at day 70 (end of study). Relative 
gene expression of human OA cartilage explants after ten weeks of culture. Patient 9, 10, 11, 13 and 14 were 
included. Gene expression was measured by RT-qPCR on RNA extracts of N2-preserved explants from 
termination of the experiment (day 70). All replicate explants for each patient and treatment were pooled for 
RNA extraction, resulting in 25 samples (5 patients x 5 treatments). The relative expression for each target 
gene (COL2A1, ACAN, SOX9 and COL1A1) in each sample was calculated by the 2−ΔΔCt method, using EIF3I 
as reference gene. Values are median (range), and the no. of samples with a detectable expression level/no. of 
samples quantified by RT-qPCR is indicated.
7Scientific RepoRtS |         (2020) 10:6011  | https://doi.org/10.1038/s41598-020-63216-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
bioactive effects when released to the synovial cavity. This statement is based on the fact that a 32-mer fragment 
of aggrecan, containing the same C-terminal sequence (NITEGE373) as detected by the AGNx1 ELISA, has been 
shown to exert anti-anabolic, pro-catabolic and pro-inflammatory effects on chondrocytes, synovial fibroblasts 
and macrophages in vitro23. Such a potential bioactivity of a bi-product of sprifermin-induced cartilage regener-
ation, is obviously important for evaluation of effects and potential side effects observed in the clinic. However, 
the decreased release of the AGNx1 fragment at late-phase culturing might indicates that long-term effects may 
be limited.
Figure 3. Proteoglycan (Safranin O/Fast Green) content at termination, individual patients.Proteoglycan 
content of human OA cartilage explants after 10 weeks of culture. Patient 4 (A), 5 (B) and 6 (C) were included. 
Proteoglycan content was evaluated by Safranin O/Fast Green staining of 5 μm sections of FFPE explants from 
termination of the experiment (day 70). Two replicate explants for each patient and treatment were stained, of 
which one representative is shown by pictures of superficial, middle and deep cartilage layer, respectively.
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The following limitations apply to the present study: Only articular cartilage was investigated without 
accounting for the influence of other joint tissues or mechanical stress. Moreover, the human OA articular car-
tilage had a high degree of variation, due to several factors. First, the cartilage was retrieved from OA patients, 
without selecting for disease-related factors, such as gender, age, obesity, inflammatory status etc. This introduces 
patient-to-patient variation. Second, the OA patients were end-stage with highly destructed cartilage, mean-
ing that the isolated cartilage was taken from the limited areas of remaining cartilage. Therefore, the anatomic 
location and the thickness of the isolated cartilage varied. We have tried to accommodate the cartilage varia-
tion by including many patients in the study, and by revealing the individual patient data in the additional files 
(see Supplementary Figs. 1–4, Additional File 2). And lastly, temporal changes in cell proliferation could not be 
analyzed due to limited volume of cartilage from each patient. Instead, metabolic activity of the explants was 
monitored over time, to control for viability and to give an indication of potential cell proliferation in response 
to sprifermin.
Conclusions
Sprifermin inducedbiphasic ECM remodeling in human knee OA articular cartilage ex vivo. This ECM remod-
eling was initiated by increased aggrecanase-activity and decreased type II collagen formation, followed by 
increased type II collagen formation. Meanwhile, the metabolic activity was continuously increased, potentially 
indicating a growing chondrocyte population in the early phase and increasing ECM production in the late phase.
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